The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Infectious Disease & AMR

Ferring, Rebiotix and MyBiotics Collaborate to Develop Microbiome Therapeutics in Reproductive Medicine and Maternal Health
Finance

Ferring, Rebiotix and MyBiotics Collaborate to Develop Microbiome Therapeutics in Reproductive Medicine and Maternal Health

FEB 19, 2021
Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132
Clinical & Manufacturing

Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132

FEB 3, 2021
Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections
Clinical & Manufacturing

Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections

JAN 20, 2021
Basic & Discovery Research

Virus Discovery and Surveillance Using Viral Metagenomics

OCT 23, 2020
Vedanta Biosciences Awarded Up to $76.9 Million to Advance Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients
Finance

Vedanta Biosciences Awarded Up to $76.9 Million to Advance Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients

OCT 1, 2020
BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for IBD
Basic & Discovery Research

BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for IBD

SEP 3, 2020
‘Oral’ bacteria may disrupt the balance of the vaginal microbiome
Basic & Discovery Research

‘Oral’ bacteria may disrupt the balance of the vaginal microbiome

SEP 1, 2020
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
Clinical & Manufacturing

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

AUG 10, 2020
Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans
Clinical & Manufacturing

Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans

MAY 11, 2020
Safety Alert Regarding Use of FMT and Additional Safety Protections Pertaining to SARS-CoV-2 and COVID-19
Finance

Safety Alert Regarding Use of FMT and Additional Safety Protections Pertaining to SARS-CoV-2 and COVID-19

MAR 24, 2020
FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms
Editor's Choice

FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms

MAR 13, 2020